Pacira BioSciences Valuation
Is 82P undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 82P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 82P (€16.7) is trading below our estimate of fair value (€81.24)
Significantly Below Fair Value: 82P is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 82P?
Key metric: As 82P is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 82P's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | US$694.96m |
| Market Cap | US$810.34m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 5.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 82P's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.2x | ||
DMP Dermapharm Holding | 1.7x | 4.1% | €2.0b |
PSG PharmaSGP Holding | 2.6x | 7.7% | €280.6m |
2FJ0 Pierrel | 3.4x | n/a | €92.8m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
82P Pacira BioSciences | 1.2x | 0.6% | €810.3m |
Price-To-Sales vs Peers: 82P is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (5.2x).
Price to Sales Ratio vs Industry
How does 82P's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: 82P is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is 82P's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 1.8x |
Price-To-Sales vs Fair Ratio: 82P is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €16.70 | €17.00 +1.8% | 50.7% | €36.82 | €7.55 | n/a | 8 |
| Nov ’25 | €15.50 | €16.86 +8.7% | 51.5% | €35.53 | €7.29 | n/a | 8 |
| Oct ’25 | €13.40 | €16.44 +22.7% | 52.1% | €34.90 | €7.16 | n/a | 8 |
| Sep ’25 | €13.80 | €16.37 +18.6% | 53.6% | €35.47 | €7.28 | n/a | 8 |
| Aug ’25 | €18.80 | €35.63 +89.5% | 23.7% | €52.82 | €23.17 | n/a | 9 |
| Jul ’25 | €26.60 | €41.26 +55.1% | 14.9% | €52.38 | €33.08 | n/a | 10 |
| Jun ’25 | €28.00 | €41.26 +47.4% | 14.9% | €52.38 | €33.08 | n/a | 10 |
| May ’25 | €23.80 | €41.38 +73.9% | 14.3% | €52.06 | €32.88 | n/a | 10 |
| Apr ’25 | €26.80 | €41.38 +54.4% | 14.3% | €52.06 | €32.88 | n/a | 10 |
| Mar ’25 | €26.80 | €42.04 +56.9% | 14.3% | €52.60 | €35.07 | n/a | 9 |
| Feb ’25 | €29.80 | €44.12 +48.0% | 13.6% | €52.75 | €35.17 | n/a | 9 |
| Jan ’25 | €30.20 | €44.09 +46.0% | 14.0% | €52.84 | €34.62 | n/a | 10 |
| Dec ’24 | €24.80 | €44.71 +80.3% | 13.8% | €52.80 | €34.59 | n/a | 9 |
| Nov ’24 | €26.20 | €51.27 +95.7% | 11.9% | €62.83 | €43.14 | €15.50 | 9 |
| Oct ’24 | €28.80 | €50.72 +76.1% | 11.9% | €61.95 | €41.91 | €13.40 | 9 |
| Sep ’24 | €32.40 | €50.72 +56.5% | 11.9% | €61.95 | €41.91 | €13.80 | 9 |
| Aug ’24 | €32.80 | €55.53 +69.3% | 15.1% | €71.91 | €43.15 | €18.80 | 9 |
| Jul ’24 | €36.40 | €57.70 +58.5% | 14.2% | €73.26 | €45.79 | €26.60 | 9 |
| Jun ’24 | €35.00 | €58.74 +67.8% | 15.3% | €72.63 | €45.40 | €28.00 | 10 |
| May ’24 | €40.40 | €59.43 +47.1% | 15.5% | €72.92 | €45.58 | €23.80 | 10 |
| Apr ’24 | €37.00 | €61.38 +65.9% | 16.2% | €74.62 | €46.64 | €26.80 | 10 |
| Mar ’24 | €40.80 | €61.39 +50.5% | 19.0% | €84.41 | €46.90 | €26.80 | 11 |
| Feb ’24 | €36.40 | €61.63 +69.3% | 18.6% | €82.79 | €46.00 | €29.80 | 11 |
| Jan ’24 | €36.20 | €68.24 +88.5% | 15.7% | €84.76 | €47.09 | €30.20 | 11 |
| Dec ’23 | €45.80 | €73.01 +59.4% | 14.3% | €89.34 | €53.61 | €24.80 | 11 |
| Nov ’23 | €52.50 | €77.77 +48.1% | 14.9% | €95.31 | €54.75 | €26.20 | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Fortrea Holdings
US$1.8b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.40
7D
2.8%
1Y
-38.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
1.3%
1Y
89.7%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
3.6%
1Y
22.9%